Lymphoma

Experts on diffuse large B-cell lymphoma discuss the factors that inform their treatment choices in the second line.

Investigators plan to initiate a phase 2 study evaluating AFM13 plus AB-101 in patients with relapsed/refractory classical Hodgkin lymphoma in the first half of 2024.

Patients with relapsed/refractory diffuse large B-cell lymphoma can now receive epcoritamab following the FDA’s approval of the agent.

Rituximab plus bendamustine and cytarabine continues to show clinical efficacy and favorable outcomes in a population of elderly patients with mantle cell lymphoma.

Experts overview the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory DLBCL, and discuss how tumor volume correlates with clinical outcomes.

An overview of the L-MIND trial of tafasitamab plus lenalidomide in patients with relapsed/refractory disease.

Investigators are expected to share initial safety and efficacy data from a phase 1/2 trial assessing IMPT-314 as a treatment for aggressive B-cell lymphoma in the second half of 2023.

Expert oncologists discuss the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL).

Andre H. Goy, MD, and Andrew Ip, MD, offer insights on the future of mantle cell lymphoma treatment.

Findings from a nested case-control study may enable individualized colorectal cancer risk estimations for Hodgkin lymphoma survivors who receive radiotherapy plus procarbazine.

The addition of pembrolizumab to conventional chemotherapy appears tolerable and effective in a cohort of patients with relapsed/refractory classic Hodgkin lymphoma, according to data from a phase 2 trial.

Experts on B-cell malignancies discuss second-line therapy options for patients with relapsed/refractory mantle cell lymphoma.

A comprehensive overview of CAR T-cell therapy as a treatment modality for mantle cell lymphoma, including insights on the ZUMA-2 clinical trial.

Liso-cel produces no new safety signals in relapsed or refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.

Expert oncologists give an overview of the BRUIN trial and discuss pirtobrutinib as a treatment for patients with mantle cell lymphoma.

Andre H. Goy, MD, and Andrew Ip, MD, discuss the ways in which treatment paradigms for mantle cell lymphoma (MCL) have recently shifted.

Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone following the FDA’s approval of the regimen.

Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

The FDA expresses openness towards having protocol discussions with investigators on initiating a second clinical study evaluating synthetic hypericin sodium for cutaneous T-cell lymphoma.

Primary outcome data from phase 3 confirmatory studies evaluating ibrutinib in mantle cell lymphoma and marginal zone lymphoma are insufficient to support conversion to full FDA approval in these indications.

Findings from the phase 3 TRANSFORM study support the Committee for Medicinal Products for Human Use’s recommendation to approve lisocabtagene maraleucel for large B-cell lymphoma.

Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.

Acceptance of an investigational new drug application for GRC 54276 will allow investigators to proceed with a phase 1/2 trial evaluating the agent in patients with advanced solid tumors and lymphomas.

According to a retrospective analysis, bendamustine treatment correlates with a higher risk of infection and second malignancy compared with other treatments for indolent B-cell lymphoma.

Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.

Findings from 2 clinical trials support the approval of acalabrutinib as a treatment for patients with mantle cell lymphoma in China.

Investigators indicate that although avoiding efficient mantle cell lymphoma treatment due to late effects may seem okay, most long-term health care needs are disease related in patients up to 70 years.

Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.

Data from a prospective pilot study indicate that circulating tumor DNA may be a valuable prognostic biomarker in early-stage follicular lymphoma.

Findings from a multicenter analysis indicate that tumor lysis syndrome is a notable risk in patients with mantle cell lymphoma receiving treatment with venetoclax.